CTOs on the Move

Elderhaus Inc

www.elderhaus.com

 
Elderhaus Inc is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.elderhaus.com
  • 1950 Amphitheater Dr
    Wilmington, NC USA 28401
  • Phone: 910.343.8209

Executives

Name Title Contact Details

Similar Companies

Michigan Academy of Family Physicians

Michigan Academy of Family Physicians is a Okemos, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pss Imaging Inc

Pss Imaging Inc is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord Services

Accord Services is a Marietta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Onsite Partners

Onsite Partners, Inc. is a holding company of behavioral services organizations: Onsite Workshops, Milestones, and Onsite at The Oaks. The Onsite family of brands provides services to thousands of clients annually from the United States and Europe, through in-person and virtual settings. Through these companies, Onsite curates transformational emotional health experiences that combine some of the best therapeutic and clinical minds in the country with its signature healing hospitality. Recently Onsite launched a series of virtual emotional health courses and will be expanding this platform in 2021. Onsite offers experiential group programs, counseling intensives, digital courses, and innovative residential trauma treatment that bolster empathy, self-awareness, compassion, and resilience. Onsite`s mission is to change lives through enhanced emotional health. Onsite`s work has been featured on 20/20, Good Morning America, New York Times, Wall Street Journal, Marie Claire, People, Dr. Phil Show, and The Doctors.

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.